Treating dyslipidemias: Is inflammation the missing link?

Medicinal Chemistry

Volumn 10, Issue 7, 2014, Pages 643-652

  Papoutsidakis, Nikolaos ^a   Deftereos, Spyridon ^b   Giannopoulos, Georgios ^b   Panagopoulou, Vasiliki ^a   Manolis, Antonis S ^c   Bouras, Georgios ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; CAD; Cholesterol; Dyslipidemia; Inflammation; Lipids

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A; APOLIPOPROTEIN B; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; STAT PROTEIN; TRANSCRIPTION FACTOR NFAT; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; CHOLESTEROL DIET; CHRONIC INFLAMMATION; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DYSLIPIDEMIA; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; DYSLIPIDEMIAS; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DYSLIPIDEMIAS; HUMANS; INFLAMMATION;

EID: 84925650171     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406410666140318101936     Document Type: Article

References (134)

1. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420(6917), 868-74.
2. Antonopoulos, A. S.; Margaritis, M.; Shirodaria, C.; Antoniades, C. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb. Haemost. 2012, 108(5), 840-8.
3. Moore, K. J.; Freeman, M. W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 2006, 26(8), 1702-11.
4. Leonarduzzi, G.; Gamba, P.; Gargiulo, S.; Biasi, F.; Poli, G. Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis. Free Radic. Biol. Med. 2012, 52(1), 19-34.
5. Jovinge, S.; Ares, M. P.; Kallin, B.; Nilsson, J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler. Thromb. Vasc. Biol. 1996, 16(12), 1573-9.
6. Terkeltaub, R.; Banka, C. L.; Solan, J.; Santoro, D.; Brand, K.; Curtiss, L. K. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler. Thromb. 1994, 14(1), 47-53.
7. Maziere, C.; Maziere, J. C. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic. Biol. Med. 2009, 46(2), 127-37.
8. Van Tits, L. J.; Stienstra, R.; Van Lent, P. L.; Netea, M. G.; Joosten, L. A.; Stalenhoef, A. F. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011, 214(2), 345-9.
9. Tsimikas, S.; Brilakis, E. S.; Miller, E. R.; McConnell, J. P.; Lennon, R. J.; Kornman, K. S.; Witztum, J. L.; Berger, P. B. Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 2005, 353(1), 46-57.
10. Erridge, C.; Spickett, C. M. Oxidised phospholipid regulation of Toll-like receptor signalling. Redox report: Commun. Free Radic. Res. 2007, 12(1), 76-80.
11. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354(9177), 447-55.
12. Lemaitre, R. N.; King, I. B.; Mozaffarian, D.; Kuller, L. H.; Tracy, R. P.; Siscovick, D. S. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am. J. Clin. Nutr. 2003, 77(2), 319-25.
13. Dessi, M.; Noce, A.; Bertucci, P.; Manca Di Villahermosa, S.; Zenobi, R.; Castagnola, V.; Addessi, E.; Di Daniele, N. Atherosclerosis, dyslipidemia, and inflammation: The significant role of polyunsaturated fatty acids. ISRN Inflamm. 2013, 2013, 191823.
14. Tabet, F.; Rye, K. A. High-density lipoproteins, inflammation and oxidative stress. Clin. Sci. (Lond.) 2009, 116(2), 87-98.
15. Ohashi, R.; Mu, H.; Wang, X.; Yao, Q.; Chen, C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 2005, 98(12), 845-56.
16. Fisher, E. A.; Feig, J. E.; Hewing, B.; Hazen, S. L.; Smith, J. D. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 2012, 32(12), 2813-20.
17. Onat, A.; Hergenc, G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011, 60(4), 499-512.
18. Glagov, S.; Weisenberg, E.; Zarins, C. K.; Stankunavicius, R.; Kolettis, G. J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 1987, 316(22), 1371-5.
19. Maiolino, G.; Rossitto, G.; Caielli, P.; Bisogni, V.; Rossi, G. P.; Calo, L. A. The role of oxidized low-density lipoproteins in atherosclerosis: The myths and the facts. Mediators Inflamm. 2013, 2013, 714653.
20. Khovidhunkit, W.; Memon, R. A.; Feingold, K. R.; Grunfeld, C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J. Infect. Dis. 2000, 181(Suppl 3), S462-72.
21. Hardardottir, I.; Grunfeld, C.; Feingold, K. R. Effects of endotoxin on lipid metabolism. Biochem. Soc. Trans. 1995, 23(4), 1013-8.
22. Scanu, A. M. Lipoprotein (a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr. Atheroscler. Rep. 2003, 5(2), 106-13.
23. Koschinsky, M. L. Lipoprotein (a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr. Atheroscler. Rep. 2005, 7(5), 389-95.
24. Gallin, J. I.; Kaye, D.; O'Leary, W. M. Serum lipids in infection. N. Engl. J. Med. 1969, 281(20), 1081-6.
25. Sammalkorpi, K.; Valtonen, V.; Kerttula, Y.; Nikkila, E.; Taskinen, M. R. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988, 37(9), 859-65.
26. Rosenzweig, I. B.; Wiebe, D. A.; Hank, J. A.; Albers, J. J.; Adolphson, J. L.; Borden, E.; Shrago, E. S.; Sondel, P. M. Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein. Biotherapy 1990, 2(3), 193-8.
27. Naeem, M.; Bacon, B. R.; Mistry, B.; Britton, R. S.; Di Bisceglie, A. M. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am. J. Gastroenterol. 2001, 96(8), 2468-72.
28. Olsen, E. A.; Lichtenstein, G. R.; Wilkinson, W. E. Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-n1 (Wellferon). J. Am. Acad. Dermatol. 1988, 19 (2 Pt 1), 286-9.
29. Sherman, M. L.; Spriggs, D. R.; Arthur, K. A.; Imamura, K.; Frei, E. 3rd; Kufe, D. W. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J. Clin. Oncol. 1988, 6(2), 344-50.
30. Hudgins, L. C.; Parker, T. S.; Levine, D. M.; Gordon, B. R.; Saal, S. D.; Jiang, X. C.; Seidman, C. E.; Tremaroli, J. D.; Lai, J.; Rubin, A. L. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J. Lipid Res. 2003, 44(8), 1489-98.
31. Fong, Y. M.; Marano, M. A.; Moldawer, L. L.; Wei, H.; Calvano, S. E.; Kenney, J. S.; Allison, A. C.; Cerami, A.; Shires, G. T.; Lowry, S. F. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J. Clin. Invest. 1990, 85(6), 1896-904.
32. Samra, J. S.; Summers, L. K.; Frayn, K. N. Sepsis and fat metabolism. Br. J. Surg. 1996, 83(9), 1186-96.
33. Feingold, K. R.; Staprans, I.; Memon, R. A.; Moser, A. H.; Shigenaga, J. K.; Doerrler, W.; Dinarello, C. A.; Grunfeld, C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J. Lipid Res. 1992, 33(12), 1765-76.
34. Fried, S. K.; Zechner, R. Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J. Lipid Res. 1989, 30(12), 1917-23.
35. Van Leeuwen, H. J.; Heezius, E. C.; Dallinga, G. M.; Van Strijp, J. A.; Verhoef, J.; Van Kessel, K. P. Lipoprotein metabolism in patients with severe sepsis. Crit. Care Med. 2003, 31(5), 1359-66.
36. Bonville, D. A.; Parker, T. S.; Levine, D. M.; Gordon, B. R.; Hydo, L. J.; Eachempati, S. R.; Barie, P. S. The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome. Surg. Infect. (Larchmt.) 2004, 5(1), 39-49.
37. Gordon, B. R.; Parker, T. S.; Levine, D. M.; Saal, S. D.; Wang, J. C.; Sloan, B. J.; Barie, P. S.; Rubin, A. L. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit. Care Med. 2001, 29(8), 1563-8.
38. Memon, R. A.; Staprans, I.; Noor, M.; Holleran, W. M.; Uchida, Y.; Moser, A. H.; Feingold, K. R.; Grunfeld, C. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 2000, 20(6), 1536-42.
39. Read, T. E.; Harris, H. W.; Grunfeld, C.; Feingold, K. R.; Kane, J. P.; Rapp, J. H. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur. Heart J. 1993, 14(Suppl K), 125-9.
40. Gordon, S. M.; Hofmann, S.; Askew, D. S.; Davidson, W. S. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol. Metab. 2011, 22(1), 9-15.
41. Borba, E. F.; Carvalho, J. F.; Bonfa, E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin. Dev. Immunol. 2006, 13(2-4), 203-8.
42. De Carvalho, J. F.; Bonfa, E.; Borba, E. F. Systemic lupus erythematosus and "lupus dyslipoproteinemia". Autoimmun. Rev., 2008, 7(3), 246-50.
43. Asanuma, Y.; Chung, C. P.; Oeser, A.; Shintani, A.; Stanley, E.; Raggi, P.; Stein, C. M. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J. Rheumatol. 2006, 33(3), 539-45.
44. Chung, C. P.; Oeser, A.; Solus, J.; Avalos, I.; Gebretsadik, T.; Shintani, A.; Linton, M. F.; Fazio, S.; Stein, C. M. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J. Rheumatol. 2007, 34(9), 1849-54.
45. Svenungsson, E.; Gunnarsson, I.; Fei, G. Z.; Lundberg, I. E.; Klareskog, L.; Frostegard, J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003, 48(9), 2533-40.
46. Reiss, A. B. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr. Rheumatol. Rep. 2009, 11(4), 255-60.
47. Choi, H. K.; Seeger, J. D. Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J. Rheumatol. 2005, 32(12), 2311-6.
48. Dursunoglu, D.; Evrengul, H.; Polat, B.; Tanriverdi, H.; Cobankara, V.; Kaftan, A.; Kilic, M. Lp (a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int. 2005, 25(4), 241-5.
49. Georgiadis, A. N.; Papavasiliou, E. C.; Lourida, E. S.; Alamanos, Y.; Kostara, C.; Tselepis, A. D.; Drosos, A. A. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res. Ther. 2006, 8(3), R82.
50. Steiner, G.; Urowitz, M. B. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin. Arthritis Rheum. 2009, 38(5), 372-81.
51. Garcia-Gomez, C.; Nolla, J. M.; Valverde, J.; Gomez-Gerique, J. A.; Castro, M. J.; Pinto, X. Conventional lipid profile and lipoprotein (a) concentrations in treated patients with rheumatoid arthritis. J. Rheumatol. 2009, 36(7), 1365-70.
52. Myasoedova, E.; Crowson, C. S.; Kremers, H. M.; Fitz-Gibbon, P. D.; Therneau, T. M.; Gabriel, S. E. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69(7), 1310-4.
53. Joven, J.; Rubies-Prat, J.; Ras, M. R.; De La Figuera, M.; Lience, E.; Masdeu, S. High density lipoprotein cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 1984, 27(10), 1199-200.
54. Van Halm, V. P.; Van Denderen, J. C.; Peters, M. J.; Twisk, J. W.; Van Der Paardt, M.; Van Der Horst-Bruinsma, I. E.; Van De Stadt, R. J.; De Koning, M. H.; Dijkmans, B. A.; Nurmohamed, M. T. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2006, 65(11), 1473-7.
55. Lazarevic, M. B.; Vitic, J.; Mladenovic, V.; Myones, B. L.; Skosey, J. L.; Swedler, W. I. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin. Arthritis Rheum. 1992, 22(3), 172-8.
56. Jones, S. M.; Harris, C. P.; Lloyd, J.; Stirling, C. A.; Reckless, J. P.; McHugh, N. J. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann. Rheum. Dis. 2000, 59(11), 904-9.
57. Lee, J. B.; Yi, H. Y.; Bae, K. H. The association between periodontitis and dyslipidemia based on the Fourth Korea National Health and Nutrition Examination Survey. J. Clin. Periodontol. 2013, 40(5), 437-42.
58. Nibali, L.; D'Aiuto, F.; Griffiths, G.; Patel, K.; Suvan, J.; Tonetti, M. S. Severe periodontitis is associated with systemic inflammation and a dysmetabolic status: a case-control study. J. Clin. Periodontol. 2007, 34(11), 931-7.
59. Monteiro, A. M.; Jardini, M. A.; Alves, S.; Giampaoli, V.; Aubin, E. C.; Figueiredo Neto, A. M.; Gidlund, M. Cardiovascular disease parameters in periodontitis. J. Periodontol. 2009, 80(3), 378-88.
60. Oz, S. G.; Fentoglu, O.; Kilicarslan, A.; Guven, G. S.; Tanrtover, M. D.; Aykac, Y.; Sozen, T. Beneficial effects of periodontal treatment on metabolic control of hypercholesterolemia. South. Med. J. 2007, 100(7), 686-91.
61. Pejcic, A.; Kesic, L.; Brkic, Z.; Pesic, Z.; Mirkovic, D. Effect of periodontal treatment on lipoproteins levels in plasma in patients with periodontitis. South. Med. J. 2011, 104(8), 547-52.
62. Altay, U.; Gurgan, C. A.; Agbaht, K. Changes in inflammatory and metabolic parameters after periodontal treatment in patients with and without obesity. J. Periodontol. 2013, 84(1), 13-23.
63. Tannock, L. R.; O'Brien, K. D.; Knopp, R. H.; Retzlaff, B.; Fish, B.; Wener, M. H.; Kahn, S. E.; Chait, A. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005, 111(23), 3058-62.
64. Visser, M.; Bouter, L. M.; McQuillan, G. M.; Wener, M. H.; Harris, T. B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282(22), 2131-5.
65. Cani, P. D.; Amar, J.; Iglesias, M. A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A. M.; Fava, F.; Tuohy, K. M.; Chabo, C.; Waget, A.; Delmee, E.; Cousin, B.; Sulpice, T.; Chamontin, B.; Ferrieres, J.; Tanti, J. F.; Gibson, G. R.; Casteilla, L.; Delzenne, N. M.; Alessi, M. C.; Burcelin, R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56(7), 1761-72.
66. Kleemann, R.; Verschuren, L.; Van Erk, M. J.; Nikolsky, Y.; Cnubben, N. H.; Verheij, E. R.; Smilde, A. K.; Hendriks, H. F.; Zadelaar, S.; Smith, G. J.; Kaznacheev, V.; Nikolskaya, T.; Melnikov, A.; Hurt-Camejo, E.; Van Der Greef, J.; Van Ommen, B.; Kooistra, T. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 2007, 8(9), R200.
67. Cai, D.; Yuan, M.; Frantz, D. F.; Melendez, P. A.; Hansen, L.; Lee, J.; Shoelson, S. E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11(2), 183-90.
68. Wielinga, P. Y.; Yakala, G. K.; Heeringa, P.; Kleemann, R.; Kooistra, T. Beneficial effects of alternate dietary regimen on liver inflammation, atherosclerosis and renal activation. PloS One 2011, 6(3), e18432.
69. ∗3-Leiden mice. Atherosclerosis 2012, 220(2), 362-8.
70. Joffe, Y. T.; Collins, M.; Goedecke, J. H. The relationship between dietary fatty acids and inflammatory genes on the obese phenotype and serum lipids. Nutrients 2013, 5(5), 1672-705.
71. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285(19), 2486-97.
72. Grundy, S. M.; Brewer, H. B. Jr.; Cleeman, J. I.; Smith, S. C.; Jr.; Lenfant, C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler. Thromb. Vasc. Biol. 2004, 24(2), e13-8.
73. Alberti, K. G.; Zimmet, P.; Shaw, J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366(9491), 1059-62.
74. Onat, A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin. Pharmacother. 2011, 12(12), 1887-1900.
75. Gomez-Guerrero, C.; Mallavia, B.; Egido, J. Targeting inflammation in cardiovascular diseases. still a neglected field? Cardiovasc. Ther. 2012, 30(4), e189-97.
76. Van Der Valk, F. M.; Van Wijk, D. F.; Stroes, E. S. Novel antiinflammatory strategies in atherosclerosis. Curr. Opin. Lipidol. 2012, 23(6), 532-9.
77. Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351(17), 1709-11.
78. Reiss, A. B.; Anwar, F.; Chan, E. S.; Anwar, K. Disruption of cholesterol efflux by coxib medications and inflammatory processes: link to increased cardiovascular risk. J. Investig. Med. 2009, 57(6), 695-702.
79. Chan, E. S.; Zhang, H.; Fernandez, P.; Edelman, S. D.; Pillinger, M. H.; Ragolia, L.; Palaia, T.; Carsons, S.; Reiss, A. B. Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res. Ther. 2007, 9(1), R4.
80. Choi, H. K.; Seeger, J. D. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005, 53(4), 528-35.
81. Leong, K. H.; Koh, E. T.; Feng, P. H.; Boey, M. L. Lipid profiles in patients with systemic lupus erythematosus. J. Rheumatol. 1994, 21(7), 1264-7.
82. Petri, M.; Spence, D.; Bone, L. R.; Hochberg, M. C. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992, 71(5), 291-302.
83. Cauza, E.; Cauza, K.; Hanusch-Enserer, U.; Etemad, M.; Dunky, A.; Kostner, K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wiener Klinische Wochenschrift 2002, 114(23-24), 1004-7.
84. Spanakis, E.; Sidiropoulos, P.; Papadakis, J.; Ganotakis, E.; Katsikas, G.; Karvounaris, S.; Bizaki, A.; Kritikos, H.; Boumpas, D. T. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J. Rheumatol. 2006, 33(12), 2440-6.
85. Popa, C.; Van Den Hoogen, F. H.; Radstake, T. R.; Netea, M. G.; Eijsbouts, A. E.; Den Heijer, M.; Van Der Meer, J. W.; Van Riel, P. L.; Stalenhoef, A. F.; Barrera, P. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66(11), 1503-7.
86. Soubrier, M.; Jouanel, P.; Mathieu, S.; Poujol, D.; Claus, D.; Dubost, J. J.; Ristori, J. M. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008, 75(1), 22-4.
87. Pollono, E. N.; Lopez-Olivo, M. A.; Lopez, J. A.; Suarez-Almazor, M. E. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin. Rheumatol. 2010, 29(9), 947-55.
88. Jacobsson, L. T.; Turesson, C.; Gulfe, A.; Kapetanovic, M. C.; Petersson, I. F.; Saxne, T.; Geborek, P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 2005, 32(7), 1213-8.
89. Kawashiri, S. Y.; Kawakami, A.; Yamasaki, S.; Imazato, T.; Iwamoto, N.; Fujikawa, K.; Aramaki, T.; Tamai, M.; Nakamura, H.; Ida, H.; Origuchi, T.; Ueki, Y.; Eguchi, K. Effects of the antiinterleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol. Int. 2011, 31(4), 451-6.
90. Sarwar, N.; Butterworth, A. S.; Freitag, D. F.; Gregson, J.; Willeit, P.; Gorman, D. N.; Gao, P.; Saleheen, D.; Rendon, A.; Nelson, C. P.; Braund, P. S.; Hall, A. S.; Chasman, D. I.; Tybjaerg-Hansen, A.; Chambers, J. C.; Benjamin, E. J.; Franks, P. W.; Clarke, R.; Wilde, A. A.; Trip, M. D.; Steri, M.; Witteman, J. C.; Qi, L.; Van Der Schoot, C. E.; De Faire, U.; Erdmann, J.; Stringham, H. M.; Koenig, W.; Rader, D. J.; Melzer, D.; Reich, D.; Psaty, B. M.; Kleber, M. E.; Panagiotakos, D. B.; Willeit, J.; Wennberg, P.; Woodward, M.; Adamovic, S.; Rimm, E. B.; Meade, T. W.; Gillum, R. F.; Shaffer, J. A.; Hofman, A.; Onat, A.; Sundstrom, J.; Wassertheil-Smoller, S.; Mellstrom, D.; Gallacher, J.; Cushman, M.; Tracy, R. P.; Kauhanen, J.; Karlsson, M.; Salonen, J. T.; Wilhelmsen, L.; Amouyel, P.; Cantin, B.; Best, L. G.; Ben-Shlomo, Y.; Manson, J. E.; Davey-Smith, G.; De Bakker, P. I.; O'Donnell, C. J.; Wilson, J. F.; Wilson, A. G.; Assimes, T. L.; Jansson, J. O.; Ohlsson, C.; Tivesten, A.; Ljunggren, O.; Reilly, M. P.; Hamsten, A.; Ingelsson, E.; Cambien, F.; Hung, J.; Thomas, G. N.; Boehnke, M.; Schunkert, H.; Asselbergs, F. W.; Kastelein, J. J.; Gudnason, V.; Salomaa, V.; Harris, T. B.; Kooner, J. S.; Allin, K. H.; Nordestgaard, B. G.; Hopewell, J. C.; Goodall, A. H.; Ridker, P. M.; Holm, H.; Watkins, H.; Ouwehand, W. H.; Samani, N. J.; Kaptoge, S.; Di Angelantonio, E.; Harari, O.; Danesh, J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379(9822), 1205-13.
91. Hingorani, A. D.; Casas, J. P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012, 379(9822), 1214-24.
92. Hashizume, M.; Yoshida, H.; Koike, N.; Suzuki, M.; Mihara, M. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann. Rheum. Dis. 2010, 69(4), 741-6.
93. Chan, E. S.; Cronstein, B. N. Methotrexate-how does it really work? Nat. Rev. Rheumatol. 2010, 6(3), 175-8.
94. Prodanovich, S.; Ma, F.; Taylor, J. R.; Pezon, C.; Fasihi, T.; Kirsner, R. S. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J. Am. Acad. Dermatol. 2005, 52(2), 262-7.
95. Choi, H. K.; Hernan, M. A.; Seeger, J. D.; Robins, J. M.; Wolfe, F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359(9313), 1173-7.
96. Westlake, S. L.; Colebatch, A. N.; Baird, J.; Kiely, P.; Quinn, M.; Choy, E.; Ostor, A. J.; Edwards, C. J. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010, 49(2), 295-307.
97. Park, Y. B.; Choi, H. K.; Kim, M. Y.; Lee, W. K.; Song, J.; Kim, D. K.; Lee, S. K. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am. J. Med. 2002, 113(3), 188-93.
98. Reiss, A. B.; Carsons, S. E.; Anwar, K.; Rao, S.; Edelman, S. D.; Zhang, H.; Fernandez, P.; Cronstein, B. N.; Chan, E. S. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008, 58(12), 3675-83.
99. Coomes, E.; Chan, E. S.; Reiss, A. B. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol 2011, 2011, 503028.
100. Bulgarelli, A.; Martins Dias, A. A.; Caramelli, B.; Maranhao, R. C. Treatment with methotrexate inhibits atherogenesis in cholesterolfed rabbits. J. Cardiovasc. Pharmacol. 2012, 59(4), 308-14.
101. Ridker, P. M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost. 2009, 7(Suppl 1), 332-9.
102. Rubulis, A.; Rubert, M.; Faloon, W. W. Cholesterol lowering, fecal bile acid, and sterol changes during neomycin and colchicine. Am. J. Clin. Nutr. 1970, 23(9), 1251-9.
103. Wojcicki, J.; Hinek, A.; Jaworska, M.; Samochowiec, L. The effect of colchicine on the development of experimental atherosclerosis in rabbits. Pol. J. Pharmacol. Pharm. 1986, 38(4), 343-8.
104. Field, F. J.; Albright, E.; Mathur, S. N. Regulation of triglyceriderich lipoprotein secretion by fatty acids in CaCo-2 cells. J. Lipid Res. 1988, 29(11), 1427-37.
105. Nidorf, S. M.; Eikelboom, J. W.; Budgeon, C. A.; Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013, 61(4), 404-10.
106. Sommariva, D.; Bonfiglioli, D.; Zanaboni, L.; Fasoli, A. Effects of acetylsalicylic acid on plasma lipids and on post-heparin lipase activities. Int. J. Clin. Pharmacol. Ther. Toxicol. 1981, 19(3), 112-6.
107. Higgs, G. A.; Salmon, J. A.; Henderson, B.; Vane, J. R. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc. Natl. Acad. Sci. U. S. A. 1987, 84(5), 1417-20.
108. Beynen, A. C.; Buechler, K. F.; Van Der Molen, A. J.; Geelen, M. J. Inhibition of hepatic lipogenesis by salicylate. Toxicology 1982, 24(1), 33-43.
109. Van Diepen, J. A.; Vroegrijk, I. O.; Berbee, J. F.; Shoelson, S. E.; Romijn, J. A.; Havekes, L. M.; Rensen, P. C.; Voshol, P. J. Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 2011, 301(6), E1099-107.
110. De Vries-Van Der Weij, J.; Toet, K.; Zadelaar, S.; Wielinga, P. Y.; Kleemann, R.; Rensen, P. C.; Kooistra, T. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-kappaB activity and lowering of cholesterol. Atherosclerosis 2010, 213(1), 241-6.
111. Van Diepen, J. A.; Wong, M. C.; Guigas, B.; Bos, J.; Stienstra, R.; Hodson, L.; Shoelson, S. E.; Berbee, J. F.; Rensen, P. C.; Romijn, J. A.; Havekes, L. M.; Voshol, P. J. Hepatocyte-specific IKK-beta activation enhances VLDL-triglyceride production in APOE∗3-Leiden mice. J. Lipid Res. 2011, 52(5), 942-50.
112. Tsai, J.; Zhang, R.; Qiu, W.; Su, Q.; Naples, M.; Adeli, K. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296(6), G1287-98.
113. Lewis, G. F.; Steiner, G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996, 19(4), 390-3.
114. Stienstra, R.; Saudale, F.; Duval, C.; Keshtkar, S.; Groener, J. E.; Van Rooijen, N.; Staels, B.; Kersten, S.; Muller, M. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51(2), 511-22.
115. Huang, W.; Metlakunta, A.; Dedousis, N.; Zhang, P.; Sipula, I.; Dube, J. J.; Scott, D. K.; O'Doherty, R. M. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 2010, 59(2), 347-57.
116. Ridker, P. M.; Howard, C. P.; Walter, V.; Everett, B.; Libby, P.; Hensen, J.; Thuren, T. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebocontrolled trial. Circulation 2012, 126(23), 2739-48.
117. Desai, N. R.; Giugliano, R. P.; Zhou, J.; Kohli, P.; Somaratne, R.; Hoffman, E.; Liu, T.; Scott, R.; Wasserman, S. M.; Sabatine, M. S. AMG 145, A Monoclonal Antibody Against PCSK9, Facilitates Achievement of NCEP-ATP III LDL-C Goals Among High Risk Patients: An Analysis From the LAPLACE-TIMI 57 Trial. J. Am. Coll. Cardiol. 2014, 63(5), 430-3.
118. Urban, D.; Poss, J.; Bohm, M.; Laufs, U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J. Am. Coll. Cardiol. 2013, 62(16), 1401-8.
119. Sattar, N.; Preiss, D.; Murray, H. M.; Welsh, P.; Buckley, B. M.; De Craen, A. J.; Seshasai, S. R.; McMurray, J. J.; Freeman, D. J.; Jukema, J. W.; Macfarlane, P. W.; Packard, C. J.; Stott, D. J.; Westendorp, R. G.; Shepherd, J.; Davis, B. R.; Pressel, S. L.; Marchioli, R.; Marfisi, R. M.; Maggioni, A. P.; Tavazzi, L.; Tognoni, G.; Kjekshus, J.; Pedersen, T. R.; Cook, T. J.; Gotto, A. M.; Clearfield, M. B.; Downs, J. R.; Nakamura, H.; Ohashi, Y.; Mizuno, K.; Ray, K. K.; Ford, I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375(9716), 735-42.
120. Steg, P. G.; James, S. K.; Atar, D.; Badano, L. P.; Blomstrom-Lundqvist, C.; Borger, M. A.; Di Mario, C.; Dickstein, K.; Ducrocq, G.; Fernandez-Aviles, F.; Gershlick, A. H.; Giannuzzi, P.; Halvorsen, S.; Huber, K.; Juni, P.; Kastrati, A.; Knuuti, J.; Lenzen, M. J.; Mahaffey, K. W.; Valgimigli, M.; Van 't Hof, A.; Widimsky, P.; Zahger, D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012, 33(20), 2569-619.
121. Hamm, C. W.; Bassand, J. P.; Agewall, S.; Bax, J.; Boersma, E.; Bueno, H.; Caso, P.; Dudek, D.; Gielen, S.; Huber, K.; Ohman, M.; Petrie, M. C.; Sonntag, F.; Uva, M. S.; Storey, R. F.; Wijns, W.; Zahger, D. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2011, 32(23), 2999-3054.
122. O'Gara, P. T.; Kushner, F. G.; Ascheim, D. D.; Casey, D. E. Jr.; Chung, M. K.; De Lemos, J. A.; Ettinger, S. M.; Fang, J. C.; Fesmire, F. M.; Franklin, B. A.; Granger, C. B.; Krumholz, H. M.; Linderbaum, J. A.; Morrow, D. A.; Newby, L. K.; Ornato, J. P.; Ou, N.; Radford, M. J.; Tamis-Holland, J. E.; Tommaso, C. L.; Tracy, C. M.; Woo, Y. J.; Zhao, D. X.; Anderson, J. L.; Jacobs, A. K.; Halperin, J. L.; Albert, N. M.; Brindis, R. G.; Creager, M. A.; De Mets, D.; Guyton, R. A.; Hochman, J. S.; Kovacs, R. J.; Ohman, E. M.; Stevenson, W. G.; Yancy, C. W. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013, 61(4), 485-510.
123. Anderson, J. L.; Adams, C. D.; Antman, E. M.; Bridges, C. R.; Califf, R. M.; Casey, D. E. Jr.; Chavey, W. E., 2nd; Fesmire, F. M.; Hochman, J. S.; Levin, T. N.; Lincoff, A. M.; Peterson, E. D.; Theroux, P.; Wenger, N. K.; Wright, R. S.; Jneid, H.; Ettinger, S. M.; Ganiats, T. G.; Philippides, G. J.; Jacobs, A. K.; Halperin, J. L.; Albert, N. M.; Creager, M. A.; De Mets, D.; Guyton, R. A.; Kushner, F. G.; Ohman, E. M.; Stevenson, W.; Yancy, C. W. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013, 61(23), e179-347.
124. Devaraj, S.; Chan, E.; Jialal, I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J. Clin. Endocrinol. Metab. 2006, 91(11), 4489-96.
125. Fraunberger, P.; Grone, E.; Grone, H. J.; Walli, A. K. Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. Shock 2009, 32(2), 159-63.
126. Wang, J.; Tokoro, T.; Higa, S.; Kitajima, I. Anti-inflammatory effect of pitavastatin on NF-kappaB activated by TNF-alpha in hepatocellular carcinoma cells. Biol. Pharm. Bull. 2006, 29(4), 634-9.
127. Kleemann, R.; Verschuren, L.; De Rooij, B. J.; Lindeman, J.; De Maat, M. M.; Szalai, A. J.; Princen, H. M.; Kooistra, T. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103(11), 4188-94.
128. Olteanu, D.; Nagy, A.; Dudea, M.; Filip, A.; Muresan, A.; Catoi, C.; Mircea, P. A.; Clichici, S. Hepatic and systemic effects of rosuvastatin on an experimental model of bile duct ligation in rats. J. Physiol. Pharmacol. 2012, 63(5), 483-96.
129. Shah, A.; Rader, D. J.; Millar, J. S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010, 210(1), 35-40.
130. Genolet, R.; Wahli, W.; Michalik, L. PPARs as drug targets to modulate inflammatory responses? Curr. Drug Targets Inflamm. Allergy 2004, 3(4), 361-75.
131. Zandbergen, F.; Plutzky, J. PPARalpha in atherosclerosis and inflammation. Biochim. Biophys. Acta 2007, 1771(8), 972-82.
132. Nissen, S. E.; Nicholls, S. J.; Wolski, K.; Howey, D. C.; McErlean, E.; Wang, M. D.; Gomez, E. V.; Russo, J. M. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007, 297(12), 1362-73.
133. Terra, S. G.; Francone, O. L.; Contant, C. F.; Gao, X.; Lewin, A. J.; Nguyen, T. T. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. Am. J. Cardiol. 2008, 102(4), 434-9.
134. Ridker, P. M. Closing the loop on inflammation and atherothrombosis: why perform the cirt and cantos trials? Trans. Am. Clin. Climatol. Assoc. 2013, 124, 174-90.